Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.48 |
| ▸ | CNR1 | P21554 | 1/20 | 0.48 |
| ▸ | CNR2 | P34972 | 1/20 | 0.48 |
| ▸ | LPAR1 | Q92633 | 1/20 | 0.47 |
| ▸ | LPAR3 | Q9UBY5 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30381843 | 1.00 | ALDH1A1 (0.48) | ALDH1A1CNR1CNR2LPAR1LPAR3 | |
| SCHEMBL899325 | 1.00 | ALDH1A1 (0.48) | ALDH1A1CNR1CNR2LPAR1LPAR3 | |
| SCHEMBL899266 | 1.00 | ALDH1A1 (0.48) | ALDH1A1CNR1CNR2LPAR1LPAR3 | |
| SCHEMBL25362066 | 1.00 | ALDH1A1 (0.48) | ALDH1A1CNR1CNR2LPAR1LPAR3 | |
| SCHEMBL899522 | 1.00 | ALDH1A1 (0.48) | ALDH1A1CNR1CNR2LPAR1LPAR3 | |
| SCHEMBL25411331 | 1.00 | ALDH1A1 (0.48) | ALDH1A1CNR1CNR2LPAR1LPAR3 | |
| SCHEMBL899521 | 1.00 | ALDH1A1 (0.48) | ALDH1A1CNR1CNR2LPAR1LPAR3 | |
| SCHEMBL899581 | 1.00 | ALDH1A1 (0.48) | ALDH1A1CNR1CNR2LPAR1LPAR3 | |
| SCHEMBL899326 | 1.00 | ALDH1A1 (0.48) | ALDH1A1CNR1CNR2LPAR1LPAR3 | |
| SCHEMBL30381834 | 1.00 | ALDH1A1 (0.48) | ALDH1A1CNR1CNR2LPAR1LPAR3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 47 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20150284316-A1 | LOW MOLECULAR WEIGHT CATIONIC LIPIDS FOR OLIGONUCLEOTIDE DELIVERY | BANK OF AMERICA, N.A. | 2015-10-08 | — | — | US | claimed |
| US-9029604-B2 | Low molecular weight cationic lipids for oligonucleotide delivery | SIRNA THERAPEUTICS, INC. (US) | 2015-05-12 | — | — | US | claimed |
| US-20130274523-A1 | LOW MOLECULAR WEIGHT CATIONIC LIPIDS FOR OLIGONUCLEOTIDE DELIVERY | BANK OF AMERICA, N.A. | 2013-10-17 | — | — | US | claimed |
| EP-2621480-A1 | LOW MOLECULAR WEIGHT CATIONIC LIPIDS FOR OLIGONUCLEOTIDE DELIVERY | Merck Sharp & Dohme Corp. (US) | 2013-08-07 | — | — | EP | claimed |
| WO-2012044638-A1 | LOW MOLECULAR WEIGHT CATIONIC LIPIDS FOR OLIGONUCLEOTIDE DELIVERY | MERCK SHARP & DOHME CORP. (US) | 2012-04-05 | — | — | WO | claimed |
| US-12545636-B2 | Acyclic lipids and methods of use thereof | RENAGADE THERAPEUTICS MANAGEMENT INC. (US) | 2026-02-10 | — | — | US | disclosed |
| US-20250319190-A1 | APOE LIPOPROTEIN SYSTEMS | KISBEE THERAPEUTICS INC (US) | 2025-10-16 | — | — | US | disclosed |
| US-20250313525-A1 | CONSTRAINED LIPIDS AND METHODS OF USE THEREOF | RENAGADE THERAPEUTICS MAN INC (US) | 2025-10-09 | — | — | US | disclosed |
| US-20250154102-A1 | CYCLIC LIPIDS AND METHODS OF USE THEREOF | RENAGADE THERAPEUTICS MAN INC (US) | 2025-05-15 | — | — | US | disclosed |
| EP-4522646-A2 | APOE LIPOPROTEIN SYSTEMS | Kisbee Therapeutics, Inc. (US) | 2025-03-19 | — | — | EP | disclosed |
| US-20250073164-A1 | IONIZABLE DISULFIDE LIPIDS AND LIPID NANOPARTICLES DERIVED THEREFROM | PROVIDENCE THERAPEUTICS HOLDINGS INC. (CA) | 2025-03-06 | — | — | US | disclosed |
| US-12215068-B2 | Constrained lipids and methods of use thereof | RENAGADE THERAPEUTICS MANAGEMENT INC. (US) | 2025-02-04 | — | — | US | disclosed |
| US-20150284316-A1 | LOW MOLECULAR WEIGHT CATIONIC LIPIDS FOR OLIGONUCLEOTIDE DELIVERY | BANK OF AMERICA, N.A. | 2015-10-08 | — | — | US | disclosed |
| US-20150284316-A1 | LOW MOLECULAR WEIGHT CATIONIC LIPIDS FOR OLIGONUCLEOTIDE DELIVERY | BANK OF AMERICA, N.A. | 2015-10-08 | — | — | US | disclosed |
| US-9029604-B2 | Low molecular weight cationic lipids for oligonucleotide delivery | SIRNA THERAPEUTICS, INC. (US) | 2015-05-12 | — | — | US | disclosed |
| US-9029604-B2 | Low molecular weight cationic lipids for oligonucleotide delivery | SIRNA THERAPEUTICS, INC. (US) | 2015-05-12 | — | — | US | disclosed |
| US-9029604-B2 | Low molecular weight cationic lipids for oligonucleotide delivery | SIRNA THERAPEUTICS, INC. (US) | 2015-05-12 | — | — | US | disclosed |
| US-20130274523-A1 | LOW MOLECULAR WEIGHT CATIONIC LIPIDS FOR OLIGONUCLEOTIDE DELIVERY | BANK OF AMERICA, N.A. | 2013-10-17 | — | — | US | disclosed |
| US-20130274523-A1 | LOW MOLECULAR WEIGHT CATIONIC LIPIDS FOR OLIGONUCLEOTIDE DELIVERY | BANK OF AMERICA, N.A. | 2013-10-17 | — | — | US | disclosed |
| US-20130274523-A1 | LOW MOLECULAR WEIGHT CATIONIC LIPIDS FOR OLIGONUCLEOTIDE DELIVERY | BANK OF AMERICA, N.A. | 2013-10-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130274523-A1 | LOW MOLECULAR WEIGHT CATIONIC LIPIDS FOR OLIGONUCLEOTIDE DELIVERY | LDLR, APOB, CETP | ALDH1A1 4090/4885CNR1 2187/4885CNR2 3051/4885 |
| US-20250313525-A1 | CONSTRAINED LIPIDS AND METHODS OF USE THEREOF | SGMS1, SGMS2, LNPEP | ALDH1A1 4876/4885CNR1 3077/4885CNR2 2889/4885 |
| US-20250319190-A1 | APOE LIPOPROTEIN SYSTEMS | APOB, APOL1, LDLR | ALDH1A1 3260/4885CNR1 3876/4885CNR2 3684/4885 |
| US-20250073164-A1 | IONIZABLE DISULFIDE LIPIDS AND LIPID NANOPARTICLES DERIVED THEREFROM | SGMS1, SGMS2, ABCB4 | ALDH1A1 3146/4885CNR1 4587/4885CNR2 4337/4885 |
| US-12545636-B2 | Acyclic lipids and methods of use thereof | PLTP, LNPEP, PCTP | ALDH1A1 4885/4885CNR1 3071/4885CNR2 2980/4885 |
| US-12215068-B2 | Constrained lipids and methods of use thereof | SGMS1, SGMS2, LNPEP | ALDH1A1 4876/4885CNR1 3077/4885CNR2 2889/4885 |
| US-20250154102-A1 | CYCLIC LIPIDS AND METHODS OF USE THEREOF | SGMS1, SGMS2, LNPEP | ALDH1A1 4882/4885CNR1 3959/4885CNR2 3947/4885 |
| US-20150284316-A1 | LOW MOLECULAR WEIGHT CATIONIC LIPIDS FOR OLIGONUCLEOTIDE DELIVERY | LDLR, APOB, CETP | ALDH1A1 4090/4885CNR1 2187/4885CNR2 3051/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.